Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.47 |
| ▸ | HTR2A | P28223 | 9/20 | 0.47 |
| ▸ | HTR2B | P41595 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924992 | 0.77 | SMN1; SMN2 (0.55) | HTR2CHTR2AHTR2BKCNH2S1PR4 | |
| SCHEMBL10458204 | 0.73 | KDM4E (0.52) | S1PR4SMN1; SMN2MEN1NPC1MAPT | |
| SCHEMBL3464755 | 0.73 | HTR2A (0.41) | HTR2CHTR2AKCNH2SMN1; SMN2MEN1 | |
| SCHEMBL23216493 | 0.72 | HTR2C (0.49) | HTR2CHTR2AHTR2BSMN1; SMN2MEN1 | |
| SCHEMBL29782302 | 0.72 | HTR2C (0.49) | HTR2CHTR2AHTR2BSMN1; SMN2MEN1 | |
| SCHEMBL10456779 | 0.71 | CA12 (0.42) | MAPT | |
| SCHEMBL10458647 | 0.71 | APP (0.43) | SMN1; SMN2NPC1MAPTRAB9ATDP1 | |
| SCHEMBL17625818 | 0.69 | GLA (0.43) | HTR2AKCNH2SMN1; SMN2MEN1MAPT | |
| SCHEMBL527228 | 0.69 | MAPT (0.40) | HTR2CHTR2AHTR2BKCNH2MEN1 | |
| SCHEMBL13248053 | 0.69 | PKM (0.56) | MAPTKMT2ATDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363624-A2 | FLUORO OXINDOLE DERIVATIVES AS MODULATORS OF KCNQ POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020156120-A1 | Fluoro oxindole derivatives as modulators of KCNQ potassium channels | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-24 | — | — | US | disclosed |
| US-6469042-B1 | ANALGESICS FOR MIGRAINES | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-22 | — | — | US | disclosed |
| WO-2002066426-A2 | FLUORO OXINDOLE DERIVATIVES AS MODULATORS OF KCNQ POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156120-A1 | Fluoro oxindole derivatives as modulators of KCNQ potassium channels | KCNQ1, KCNQ2, KCNQ3 | HTR2C 207/4885HTR2A 302/4885HTR2B 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.